MEDNAX
Market Cap
US$1.2b
Last Updated
2020/10/23 23:47 UTC
Data Sources
Company Financials +
Executive Summary
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. More Details
Rewards
Risk Analysis
Snowflake Analysis
Fair value with moderate growth potential.
Similar Companies
Share Price & News
How has MEDNAX's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MD's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.7%
MD
1.2%
US Healthcare
-0.4%
US Market
1 Year Return
-35.8%
MD
23.2%
US Healthcare
18.3%
US Market
Return vs Industry: MD underperformed the US Healthcare industry which returned 20% over the past year.
Return vs Market: MD underperformed the US Market which returned 17.8% over the past year.
Shareholder returns
| MD | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.7% | 1.2% | -0.4% |
| 30 Day | -5.1% | 14.0% | 8.0% |
| 90 Day | -24.2% | 6.8% | 9.4% |
| 1 Year | -35.8%-35.8% | 24.8%23.2% | 21.0%18.3% |
| 3 Year | -67.0%-67.0% | 36.7%30.9% | 42.1%32.7% |
| 5 Year | -79.2%-79.2% | 67.4%55.2% | 85.6%64.7% |
Price Volatility Vs. Market
How volatile is MEDNAX's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
An Intrinsic Calculation For MEDNAX, Inc. (NYSE:MD) Suggests It's 47% Undervalued1 month ago | Simply Wall St
Dominic Andreano Is The Executive VP of MEDNAX, Inc. (NYSE:MD) And They Just Sold 29% Of Their Shares1 month ago | Simply Wall St
A Look At MEDNAX's (NYSE:MD) Share Price ReturnsValuation
Is MEDNAX undervalued compared to its fair value and its price relative to the market?
48.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MD ($14.53) is trading below our estimate of fair value ($28.23)
Significantly Below Fair Value: MD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: MD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MD is good value based on its PB Ratio (1.5x) compared to the US Healthcare industry average (3x).
Next Steps
Future Growth
How is MEDNAX forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
87.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: MD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MD's is expected to become profitable in the next 3 years.
Revenue vs Market: MD's revenue is expected to decline over the next 3 years (-8% per year).
High Growth Revenue: MD's revenue is forecast to decline over the next 3 years (-8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MD's Return on Equity is forecast to be low in 3 years time (16.4%).
Next Steps
Past Performance
How has MEDNAX performed over the past 5 years?
-58.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MD is currently unprofitable.
Growing Profit Margin: MD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MD is unprofitable, and losses have increased over the past 5 years at a rate of 58.7% per year.
Accelerating Growth: Unable to compare MD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (28%).
Return on Equity
High ROE: MD has a negative Return on Equity (-145.04%), as it is currently unprofitable.
Next Steps
Financial Health
How is MEDNAX's financial position?
Financial Position Analysis
Short Term Liabilities: MD's short term assets ($688.3M) exceed its short term liabilities ($383.9M).
Long Term Liabilities: MD's short term assets ($688.3M) do not cover its long term liabilities ($2.2B).
Debt to Equity History and Analysis
Debt Level: MD's debt to equity ratio (210.2%) is considered high.
Reducing Debt: MD's debt to equity ratio has increased from 58.3% to 210.2% over the past 5 years.
Debt Coverage: MD's debt is not well covered by operating cash flow (19%).
Interest Coverage: MD is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is MEDNAX current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Mark Ordan (61 yo)
0.25
Tenure
Mr. Mark S. Ordan serves as Chief Executive Officer and Director at MEDNAX, Inc. since July 12, 2020. He had been an Independent Director of VEREIT, Inc., sole general Partner of VEREIT Operating Partnersh ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Director | 41.75yrs | US$8.07m | 2.02% $ 24.7m | |
| Senior VP & Chief Accounting Officer | 4.42yrs | US$2.07m | 0.13% $ 1.6m | |
| Executive VP | 8.42yrs | US$1.89m | 0.090% $ 1.1m | |
| CEO & Director | 0.25yr | no data | 0.078% $ 958.4k | |
| Executive VP & CFO | no data | no data | 0.028% $ 343.5k | |
| Senior VP of Finance | no data | no data | no data | |
| Senior VP | 1.75yrs | no data | no data | |
| Chief Development Officer | 6.83yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 1.75yrs | no data | no data | |
| Executive VP and Chief Strategy & Growth Officer | 1.33yrs | no data | 0.086% $ 1.1m | |
| President of Radiology Solutions | 0.75yr | no data | no data | |
| Regional President of Pacific Region | 18.75yrs | no data | no data |
3.1yrs
Average Tenure
57yo
Average Age
Experienced Management: MD's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Director | 41.75yrs | US$8.07m | 2.02% $ 24.7m | |
| CEO & Director | 0.25yr | no data | 0.078% $ 958.4k | |
| Independent Director | 17.92yrs | US$220.01k | 0.029% $ 355.4k | |
| Independent Director | 21.33yrs | US$210.01k | 0.038% $ 464.8k | |
| Independent Chairman | 0.25yr | no data | 0.031% $ 374.6k | |
| Independent Director | 0.25yr | no data | 0.014% $ 174.8k | |
| Lead Independent Director | 6.58yrs | US$235.01k | 0.15% $ 1.8m | |
| Independent Director | 5.42yrs | US$200.01k | 0.021% $ 259.8k | |
| Independent Director | 0.25yr | no data | 0.014% $ 174.6k | |
| Independent Director | 0.25yr | no data | 0.015% $ 180.3k | |
| Board Observer | 0.25yr | no data | no data | |
| Independent Director | 1.42yrs | US$245.42k | 0.018% $ 226.0k |
0.8yrs
Average Tenure
55yo
Average Age
Experienced Board: MD's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
MEDNAX, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: MEDNAX, Inc.
- Ticker: MD
- Exchange: NYSE
- Founded: 1979
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$1.225b
- Shares outstanding: 83.74m
- Website: https://www.mednax.com
Number of Employees
Location
- MEDNAX, Inc.
- 1301 Concord Terrace
- Sunrise
- Florida
- 33323
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MD | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Sep 1995 |
| PDC | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 1995 |
| MD * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Sep 1995 |
Biography
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the Uni ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/23 23:47 |
| End of Day Share Price | 2020/10/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.